Zanzalintinib plus atezolizumab improves survival in refractory metastatic colorectal cancer скачать в хорошем качестве

Zanzalintinib plus atezolizumab improves survival in refractory metastatic colorectal cancer

Dr Anwaar Saeed speaks to ecancer about the key findings from the STELLAR-303 phase III trial evaluating the combination of zanzalintinib (zanza), a novel multi-kinase inhibitor, with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer (mCRC) without microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR). Zanzalintinib targets multiple receptor tyrosine kinases, including MET, VEGFR, and TAM kinases, potentially enhancing tumour immune responsiveness to checkpoint blockade. Dr Saeed highlights that in this study, zanzalintinib plus atezolizumab demonstrated statistically significant and clinically meaningful improvements in overall and progression-free survival compared to regorafenib, representing a promising new therapeutic option for patients with refractory mCRC.